Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at Piper ...

Real Chemistry announced a pair of senior hires on Thursday, highlighted by the appointment of IPG and Omnicom alum Jeff ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Exercise can make a significant difference for patients with SMA by working alongside other medical advancements to improve ...

Ionis Pharmaceuticals IONS incurred a loss of 66 cents per share for fourth-quarter 2024, which was narrower than the Zacks ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...